[
  {
    "sentence": "On February 3, 2022 this literature search was updated in line with the previously described review protocol to ensure that the most recent publications on pediatric moderate-to-severe psoriasis are included (Figure 1) (13).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Supplementary Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The comparator arm for the adalimumab study was methotrexate while the other four studies were placebo controlled (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RRs ranged from 2.02–7.45 in PASI75 (Figure 2A) and 4.10–29.72 in PASI90 (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI75 treatment responses were seen for ustekinumab 0.375 mg/kg (RR = 7.25, 95% CI 2.83–18.58) and ustekinumab 0.75 mg/kg (RR = 7.45, 95% CI 2.91–19.06) compared to placebo in the CADMUS study (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI90 treatment responses were seen for ixekizumab (RR = 14.50, 95% CI 4.82–43.58) in the IXORA-PEDS study and for secukinumab (RR = 29.72 for low dose and RR = 27.68 for high dose) in the CAIN457A2310 study (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The pooled RR was 4.16 (95% CI 3.21–5.39) for PASI75 (Figure 2A) and 9.28 (95% CI 5.80–14.86) for PASI90 (Figure 2B), indicating that arms with biologics are significantly superior compared to control arms.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drug class\nDrug\nStudy\nNumber of included patients\n\nPASI75&\nPASI90&\n\n\n\n\n\nBiologics study arm\nControl study arm\n\n\n\n\n\n\nTNF inhibitor\nadalimumab LD#\nM04-717\n39\n37\n44%| 22%\n28%| 3%\n\n\nTNF inhibitor\nadalimumab HD#\nM04-717\n38\n37\n60%| 22%\n29%| 3%\n\n\nTNF inhibitor\netanercept\n20030211\n106\n105\n57%| 11%\n27%| 7%\n\n\nIL-17 inhibitor\nixekizumab\nIXORA-PEDS\n115\n56\n89%| 25%\n78%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab LD\nCADMUS\n37\n37\n78%| 11%\n54%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab HD\nCADMUS\n36\n37\n81%| 11%\n61%| 5%\n\n\nIL-17 inhibitor\nsecukinumab LD\nCAIN457A2310\n40\n41\n80%| 15%\n73%| 2%\n\n\nIL-17 inhibitor\nsecukinumab HD\nCAIN457A2310\n40\n41\n78%| 15%\n68%| 2%\n\n\nTNF inhibitor\netanercept\nCAIN457A2310\n41\n41\n63%| 15%\n29%| 2%\n\n\n\nOpen in a new tab\nHD, high dose; LD, low dose; PASI, Psoriasis Area and Severity Index; & proportion of patients in biologics study arm | proportion of patients in control study arm with response; # compared against methotrexate monotherapy instead of placebo.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q12w, every 12 weeks; RCT, randomized controlled trial; RR, risk ratio. $ dosed at weeks 1, 2, 3, 4, and every 4 weeks thereafter; # compared against methotrexate monotherapy instead of placebo.Funnel plot asymmetry was significant by Egger’s test for PASI90 (p = 0.017) (Supplementary Figure 2B) but not significant for PASI75 (p = 0.243) (Supplementary Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No serious infections were reported except for the study arm with adalimumab 0.4 mg/kg (3%) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; RCT, randomized controlled trial; RD, risk difference; SAE, serious adverse event.Serious adverse events in adults\nSerious adverse event incidences in adults were low in all study arms (up to 3%) with an RR of 1.08 in IL-17 inhibitors brodalumab, ixekizumab and secukinumab, and an RR of 1.09 in the IL-12/23 inhibitor ustekinumab (Supplementary Table 3).Adverse events in children\nSupplementary Figure 1 and Figure 4 show an overview of the frequency of overall AEs, overall infections, URTIs and gastroenteritis in pediatric plaque psoriasis studies with the exception of the secukinumab studies.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The relative incidence of overall AEs and overall infections was higher with etanercept (64 versus 59% and 47 versus 31%, respectively) (Supplementary Figure 1 and Table 4) and ixekizumab (56 versus 45% and 32 versus 25%, respectively) compared to placebo arms.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Supplementary material\nThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.944208/full#supplementary-material\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Materials\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022 this literature search was updated in line with the previously described review protocol to ensure that the most recent publications on pediatric moderate-to-severe psoriasis are included (Figure 1) (13).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Supplementary Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The comparator arm for the adalimumab study was methotrexate while the other four studies were placebo controlled (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RRs ranged from 2.02–7.45 in PASI75 (Figure 2A) and 4.10–29.72 in PASI90 (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI75 treatment responses were seen for ustekinumab 0.375 mg/kg (RR = 7.25, 95% CI 2.83–18.58) and ustekinumab 0.75 mg/kg (RR = 7.45, 95% CI 2.91–19.06) compared to placebo in the CADMUS study (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI90 treatment responses were seen for ixekizumab (RR = 14.50, 95% CI 4.82–43.58) in the IXORA-PEDS study and for secukinumab (RR = 29.72 for low dose and RR = 27.68 for high dose) in the CAIN457A2310 study (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The pooled RR was 4.16 (95% CI 3.21–5.39) for PASI75 (Figure 2A) and 9.28 (95% CI 5.80–14.86) for PASI90 (Figure 2B), indicating that arms with biologics are significantly superior compared to control arms.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drug class\nDrug\nStudy\nNumber of included patients\n\nPASI75&\nPASI90&\n\n\n\n\n\nBiologics study arm\nControl study arm\n\n\n\n\n\n\nTNF inhibitor\nadalimumab LD#\nM04-717\n39\n37\n44%| 22%\n28%| 3%\n\n\nTNF inhibitor\nadalimumab HD#\nM04-717\n38\n37\n60%| 22%\n29%| 3%\n\n\nTNF inhibitor\netanercept\n20030211\n106\n105\n57%| 11%\n27%| 7%\n\n\nIL-17 inhibitor\nixekizumab\nIXORA-PEDS\n115\n56\n89%| 25%\n78%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab LD\nCADMUS\n37\n37\n78%| 11%\n54%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab HD\nCADMUS\n36\n37\n81%| 11%\n61%| 5%\n\n\nIL-17 inhibitor\nsecukinumab LD\nCAIN457A2310\n40\n41\n80%| 15%\n73%| 2%\n\n\nIL-17 inhibitor\nsecukinumab HD\nCAIN457A2310\n40\n41\n78%| 15%\n68%| 2%\n\n\nTNF inhibitor\netanercept\nCAIN457A2310\n41\n41\n63%| 15%\n29%| 2%\n\n\n\nOpen in a new tab\nHD, high dose; LD, low dose; PASI, Psoriasis Area and Severity Index; & proportion of patients in biologics study arm | proportion of patients in control study arm with response; # compared against methotrexate monotherapy instead of placebo.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q12w, every 12 weeks; RCT, randomized controlled trial; RR, risk ratio. $ dosed at weeks 1, 2, 3, 4, and every 4 weeks thereafter; # compared against methotrexate monotherapy instead of placebo.Funnel plot asymmetry was significant by Egger’s test for PASI90 (p = 0.017) (Supplementary Figure 2B) but not significant for PASI75 (p = 0.243) (Supplementary Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No serious infections were reported except for the study arm with adalimumab 0.4 mg/kg (3%) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; RCT, randomized controlled trial; RD, risk difference; SAE, serious adverse event.Serious adverse events in adults\nSerious adverse event incidences in adults were low in all study arms (up to 3%) with an RR of 1.08 in IL-17 inhibitors brodalumab, ixekizumab and secukinumab, and an RR of 1.09 in the IL-12/23 inhibitor ustekinumab (Supplementary Table 3).Adverse events in children\nSupplementary Figure 1 and Figure 4 show an overview of the frequency of overall AEs, overall infections, URTIs and gastroenteritis in pediatric plaque psoriasis studies with the exception of the secukinumab studies.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The relative incidence of overall AEs and overall infections was higher with etanercept (64 versus 59% and 47 versus 31%, respectively) (Supplementary Figure 1 and Table 4) and ixekizumab (56 versus 45% and 32 versus 25%, respectively) compared to placebo arms.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Supplementary material\nThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.944208/full#supplementary-material\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Materials\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022 this literature search was updated in line with the previously described review protocol to ensure that the most recent publications on pediatric moderate-to-severe psoriasis are included (Figure 1) (13).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Supplementary Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The comparator arm for the adalimumab study was methotrexate while the other four studies were placebo controlled (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RRs ranged from 2.02–7.45 in PASI75 (Figure 2A) and 4.10–29.72 in PASI90 (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI75 treatment responses were seen for ustekinumab 0.375 mg/kg (RR = 7.25, 95% CI 2.83–18.58) and ustekinumab 0.75 mg/kg (RR = 7.45, 95% CI 2.91–19.06) compared to placebo in the CADMUS study (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI90 treatment responses were seen for ixekizumab (RR = 14.50, 95% CI 4.82–43.58) in the IXORA-PEDS study and for secukinumab (RR = 29.72 for low dose and RR = 27.68 for high dose) in the CAIN457A2310 study (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The pooled RR was 4.16 (95% CI 3.21–5.39) for PASI75 (Figure 2A) and 9.28 (95% CI 5.80–14.86) for PASI90 (Figure 2B), indicating that arms with biologics are significantly superior compared to control arms.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drug class\nDrug\nStudy\nNumber of included patients\n\nPASI75&\nPASI90&\n\n\n\n\n\nBiologics study arm\nControl study arm\n\n\n\n\n\n\nTNF inhibitor\nadalimumab LD#\nM04-717\n39\n37\n44%| 22%\n28%| 3%\n\n\nTNF inhibitor\nadalimumab HD#\nM04-717\n38\n37\n60%| 22%\n29%| 3%\n\n\nTNF inhibitor\netanercept\n20030211\n106\n105\n57%| 11%\n27%| 7%\n\n\nIL-17 inhibitor\nixekizumab\nIXORA-PEDS\n115\n56\n89%| 25%\n78%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab LD\nCADMUS\n37\n37\n78%| 11%\n54%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab HD\nCADMUS\n36\n37\n81%| 11%\n61%| 5%\n\n\nIL-17 inhibitor\nsecukinumab LD\nCAIN457A2310\n40\n41\n80%| 15%\n73%| 2%\n\n\nIL-17 inhibitor\nsecukinumab HD\nCAIN457A2310\n40\n41\n78%| 15%\n68%| 2%\n\n\nTNF inhibitor\netanercept\nCAIN457A2310\n41\n41\n63%| 15%\n29%| 2%\n\n\n\nOpen in a new tab\nHD, high dose; LD, low dose; PASI, Psoriasis Area and Severity Index; & proportion of patients in biologics study arm | proportion of patients in control study arm with response; # compared against methotrexate monotherapy instead of placebo.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q12w, every 12 weeks; RCT, randomized controlled trial; RR, risk ratio. $ dosed at weeks 1, 2, 3, 4, and every 4 weeks thereafter; # compared against methotrexate monotherapy instead of placebo.Funnel plot asymmetry was significant by Egger’s test for PASI90 (p = 0.017) (Supplementary Figure 2B) but not significant for PASI75 (p = 0.243) (Supplementary Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No serious infections were reported except for the study arm with adalimumab 0.4 mg/kg (3%) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; RCT, randomized controlled trial; RD, risk difference; SAE, serious adverse event.Serious adverse events in adults\nSerious adverse event incidences in adults were low in all study arms (up to 3%) with an RR of 1.08 in IL-17 inhibitors brodalumab, ixekizumab and secukinumab, and an RR of 1.09 in the IL-12/23 inhibitor ustekinumab (Supplementary Table 3).Adverse events in children\nSupplementary Figure 1 and Figure 4 show an overview of the frequency of overall AEs, overall infections, URTIs and gastroenteritis in pediatric plaque psoriasis studies with the exception of the secukinumab studies.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The relative incidence of overall AEs and overall infections was higher with etanercept (64 versus 59% and 47 versus 31%, respectively) (Supplementary Figure 1 and Table 4) and ixekizumab (56 versus 45% and 32 versus 25%, respectively) compared to placebo arms.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Supplementary material\nThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.944208/full#supplementary-material\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Materials\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022 this literature search was updated in line with the previously described review protocol to ensure that the most recent publications on pediatric moderate-to-severe psoriasis are included (Figure 1) (13).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Supplementary Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The comparator arm for the adalimumab study was methotrexate while the other four studies were placebo controlled (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RRs ranged from 2.02–7.45 in PASI75 (Figure 2A) and 4.10–29.72 in PASI90 (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI75 treatment responses were seen for ustekinumab 0.375 mg/kg (RR = 7.25, 95% CI 2.83–18.58) and ustekinumab 0.75 mg/kg (RR = 7.45, 95% CI 2.91–19.06) compared to placebo in the CADMUS study (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI90 treatment responses were seen for ixekizumab (RR = 14.50, 95% CI 4.82–43.58) in the IXORA-PEDS study and for secukinumab (RR = 29.72 for low dose and RR = 27.68 for high dose) in the CAIN457A2310 study (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The pooled RR was 4.16 (95% CI 3.21–5.39) for PASI75 (Figure 2A) and 9.28 (95% CI 5.80–14.86) for PASI90 (Figure 2B), indicating that arms with biologics are significantly superior compared to control arms.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drug class\nDrug\nStudy\nNumber of included patients\n\nPASI75&\nPASI90&\n\n\n\n\n\nBiologics study arm\nControl study arm\n\n\n\n\n\n\nTNF inhibitor\nadalimumab LD#\nM04-717\n39\n37\n44%| 22%\n28%| 3%\n\n\nTNF inhibitor\nadalimumab HD#\nM04-717\n38\n37\n60%| 22%\n29%| 3%\n\n\nTNF inhibitor\netanercept\n20030211\n106\n105\n57%| 11%\n27%| 7%\n\n\nIL-17 inhibitor\nixekizumab\nIXORA-PEDS\n115\n56\n89%| 25%\n78%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab LD\nCADMUS\n37\n37\n78%| 11%\n54%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab HD\nCADMUS\n36\n37\n81%| 11%\n61%| 5%\n\n\nIL-17 inhibitor\nsecukinumab LD\nCAIN457A2310\n40\n41\n80%| 15%\n73%| 2%\n\n\nIL-17 inhibitor\nsecukinumab HD\nCAIN457A2310\n40\n41\n78%| 15%\n68%| 2%\n\n\nTNF inhibitor\netanercept\nCAIN457A2310\n41\n41\n63%| 15%\n29%| 2%\n\n\n\nOpen in a new tab\nHD, high dose; LD, low dose; PASI, Psoriasis Area and Severity Index; & proportion of patients in biologics study arm | proportion of patients in control study arm with response; # compared against methotrexate monotherapy instead of placebo.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q12w, every 12 weeks; RCT, randomized controlled trial; RR, risk ratio. $ dosed at weeks 1, 2, 3, 4, and every 4 weeks thereafter; # compared against methotrexate monotherapy instead of placebo.Funnel plot asymmetry was significant by Egger’s test for PASI90 (p = 0.017) (Supplementary Figure 2B) but not significant for PASI75 (p = 0.243) (Supplementary Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No serious infections were reported except for the study arm with adalimumab 0.4 mg/kg (3%) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; RCT, randomized controlled trial; RD, risk difference; SAE, serious adverse event.Serious adverse events in adults\nSerious adverse event incidences in adults were low in all study arms (up to 3%) with an RR of 1.08 in IL-17 inhibitors brodalumab, ixekizumab and secukinumab, and an RR of 1.09 in the IL-12/23 inhibitor ustekinumab (Supplementary Table 3).Adverse events in children\nSupplementary Figure 1 and Figure 4 show an overview of the frequency of overall AEs, overall infections, URTIs and gastroenteritis in pediatric plaque psoriasis studies with the exception of the secukinumab studies.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The relative incidence of overall AEs and overall infections was higher with etanercept (64 versus 59% and 47 versus 31%, respectively) (Supplementary Figure 1 and Table 4) and ixekizumab (56 versus 45% and 32 versus 25%, respectively) compared to placebo arms.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Supplementary material\nThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.944208/full#supplementary-material\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Materials\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022 this literature search was updated in line with the previously described review protocol to ensure that the most recent publications on pediatric moderate-to-severe psoriasis are included (Figure 1) (13).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Supplementary Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The comparator arm for the adalimumab study was methotrexate while the other four studies were placebo controlled (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RRs ranged from 2.02–7.45 in PASI75 (Figure 2A) and 4.10–29.72 in PASI90 (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI75 treatment responses were seen for ustekinumab 0.375 mg/kg (RR = 7.25, 95% CI 2.83–18.58) and ustekinumab 0.75 mg/kg (RR = 7.45, 95% CI 2.91–19.06) compared to placebo in the CADMUS study (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI90 treatment responses were seen for ixekizumab (RR = 14.50, 95% CI 4.82–43.58) in the IXORA-PEDS study and for secukinumab (RR = 29.72 for low dose and RR = 27.68 for high dose) in the CAIN457A2310 study (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The pooled RR was 4.16 (95% CI 3.21–5.39) for PASI75 (Figure 2A) and 9.28 (95% CI 5.80–14.86) for PASI90 (Figure 2B), indicating that arms with biologics are significantly superior compared to control arms.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drug class\nDrug\nStudy\nNumber of included patients\n\nPASI75&\nPASI90&\n\n\n\n\n\nBiologics study arm\nControl study arm\n\n\n\n\n\n\nTNF inhibitor\nadalimumab LD#\nM04-717\n39\n37\n44%| 22%\n28%| 3%\n\n\nTNF inhibitor\nadalimumab HD#\nM04-717\n38\n37\n60%| 22%\n29%| 3%\n\n\nTNF inhibitor\netanercept\n20030211\n106\n105\n57%| 11%\n27%| 7%\n\n\nIL-17 inhibitor\nixekizumab\nIXORA-PEDS\n115\n56\n89%| 25%\n78%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab LD\nCADMUS\n37\n37\n78%| 11%\n54%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab HD\nCADMUS\n36\n37\n81%| 11%\n61%| 5%\n\n\nIL-17 inhibitor\nsecukinumab LD\nCAIN457A2310\n40\n41\n80%| 15%\n73%| 2%\n\n\nIL-17 inhibitor\nsecukinumab HD\nCAIN457A2310\n40\n41\n78%| 15%\n68%| 2%\n\n\nTNF inhibitor\netanercept\nCAIN457A2310\n41\n41\n63%| 15%\n29%| 2%\n\n\n\nOpen in a new tab\nHD, high dose; LD, low dose; PASI, Psoriasis Area and Severity Index; & proportion of patients in biologics study arm | proportion of patients in control study arm with response; # compared against methotrexate monotherapy instead of placebo.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q12w, every 12 weeks; RCT, randomized controlled trial; RR, risk ratio. $ dosed at weeks 1, 2, 3, 4, and every 4 weeks thereafter; # compared against methotrexate monotherapy instead of placebo.Funnel plot asymmetry was significant by Egger’s test for PASI90 (p = 0.017) (Supplementary Figure 2B) but not significant for PASI75 (p = 0.243) (Supplementary Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No serious infections were reported except for the study arm with adalimumab 0.4 mg/kg (3%) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; RCT, randomized controlled trial; RD, risk difference; SAE, serious adverse event.Serious adverse events in adults\nSerious adverse event incidences in adults were low in all study arms (up to 3%) with an RR of 1.08 in IL-17 inhibitors brodalumab, ixekizumab and secukinumab, and an RR of 1.09 in the IL-12/23 inhibitor ustekinumab (Supplementary Table 3).Adverse events in children\nSupplementary Figure 1 and Figure 4 show an overview of the frequency of overall AEs, overall infections, URTIs and gastroenteritis in pediatric plaque psoriasis studies with the exception of the secukinumab studies.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The relative incidence of overall AEs and overall infections was higher with etanercept (64 versus 59% and 47 versus 31%, respectively) (Supplementary Figure 1 and Table 4) and ixekizumab (56 versus 45% and 32 versus 25%, respectively) compared to placebo arms.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Supplementary material\nThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.944208/full#supplementary-material\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Materials\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022 this literature search was updated in line with the previously described review protocol to ensure that the most recent publications on pediatric moderate-to-severe psoriasis are included (Figure 1) (13).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Supplementary Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The comparator arm for the adalimumab study was methotrexate while the other four studies were placebo controlled (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RRs ranged from 2.02–7.45 in PASI75 (Figure 2A) and 4.10–29.72 in PASI90 (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI75 treatment responses were seen for ustekinumab 0.375 mg/kg (RR = 7.25, 95% CI 2.83–18.58) and ustekinumab 0.75 mg/kg (RR = 7.45, 95% CI 2.91–19.06) compared to placebo in the CADMUS study (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI90 treatment responses were seen for ixekizumab (RR = 14.50, 95% CI 4.82–43.58) in the IXORA-PEDS study and for secukinumab (RR = 29.72 for low dose and RR = 27.68 for high dose) in the CAIN457A2310 study (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The pooled RR was 4.16 (95% CI 3.21–5.39) for PASI75 (Figure 2A) and 9.28 (95% CI 5.80–14.86) for PASI90 (Figure 2B), indicating that arms with biologics are significantly superior compared to control arms.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drug class\nDrug\nStudy\nNumber of included patients\n\nPASI75&\nPASI90&\n\n\n\n\n\nBiologics study arm\nControl study arm\n\n\n\n\n\n\nTNF inhibitor\nadalimumab LD#\nM04-717\n39\n37\n44%| 22%\n28%| 3%\n\n\nTNF inhibitor\nadalimumab HD#\nM04-717\n38\n37\n60%| 22%\n29%| 3%\n\n\nTNF inhibitor\netanercept\n20030211\n106\n105\n57%| 11%\n27%| 7%\n\n\nIL-17 inhibitor\nixekizumab\nIXORA-PEDS\n115\n56\n89%| 25%\n78%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab LD\nCADMUS\n37\n37\n78%| 11%\n54%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab HD\nCADMUS\n36\n37\n81%| 11%\n61%| 5%\n\n\nIL-17 inhibitor\nsecukinumab LD\nCAIN457A2310\n40\n41\n80%| 15%\n73%| 2%\n\n\nIL-17 inhibitor\nsecukinumab HD\nCAIN457A2310\n40\n41\n78%| 15%\n68%| 2%\n\n\nTNF inhibitor\netanercept\nCAIN457A2310\n41\n41\n63%| 15%\n29%| 2%\n\n\n\nOpen in a new tab\nHD, high dose; LD, low dose; PASI, Psoriasis Area and Severity Index; & proportion of patients in biologics study arm | proportion of patients in control study arm with response; # compared against methotrexate monotherapy instead of placebo.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q12w, every 12 weeks; RCT, randomized controlled trial; RR, risk ratio. $ dosed at weeks 1, 2, 3, 4, and every 4 weeks thereafter; # compared against methotrexate monotherapy instead of placebo.Funnel plot asymmetry was significant by Egger’s test for PASI90 (p = 0.017) (Supplementary Figure 2B) but not significant for PASI75 (p = 0.243) (Supplementary Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No serious infections were reported except for the study arm with adalimumab 0.4 mg/kg (3%) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; RCT, randomized controlled trial; RD, risk difference; SAE, serious adverse event.Serious adverse events in adults\nSerious adverse event incidences in adults were low in all study arms (up to 3%) with an RR of 1.08 in IL-17 inhibitors brodalumab, ixekizumab and secukinumab, and an RR of 1.09 in the IL-12/23 inhibitor ustekinumab (Supplementary Table 3).Adverse events in children\nSupplementary Figure 1 and Figure 4 show an overview of the frequency of overall AEs, overall infections, URTIs and gastroenteritis in pediatric plaque psoriasis studies with the exception of the secukinumab studies.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The relative incidence of overall AEs and overall infections was higher with etanercept (64 versus 59% and 47 versus 31%, respectively) (Supplementary Figure 1 and Table 4) and ixekizumab (56 versus 45% and 32 versus 25%, respectively) compared to placebo arms.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Supplementary material\nThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.944208/full#supplementary-material\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Materials\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022 this literature search was updated in line with the previously described review protocol to ensure that the most recent publications on pediatric moderate-to-severe psoriasis are included (Figure 1) (13).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Supplementary Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The comparator arm for the adalimumab study was methotrexate while the other four studies were placebo controlled (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RRs ranged from 2.02–7.45 in PASI75 (Figure 2A) and 4.10–29.72 in PASI90 (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI75 treatment responses were seen for ustekinumab 0.375 mg/kg (RR = 7.25, 95% CI 2.83–18.58) and ustekinumab 0.75 mg/kg (RR = 7.45, 95% CI 2.91–19.06) compared to placebo in the CADMUS study (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI90 treatment responses were seen for ixekizumab (RR = 14.50, 95% CI 4.82–43.58) in the IXORA-PEDS study and for secukinumab (RR = 29.72 for low dose and RR = 27.68 for high dose) in the CAIN457A2310 study (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The pooled RR was 4.16 (95% CI 3.21–5.39) for PASI75 (Figure 2A) and 9.28 (95% CI 5.80–14.86) for PASI90 (Figure 2B), indicating that arms with biologics are significantly superior compared to control arms.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drug class\nDrug\nStudy\nNumber of included patients\n\nPASI75&\nPASI90&\n\n\n\n\n\nBiologics study arm\nControl study arm\n\n\n\n\n\n\nTNF inhibitor\nadalimumab LD#\nM04-717\n39\n37\n44%| 22%\n28%| 3%\n\n\nTNF inhibitor\nadalimumab HD#\nM04-717\n38\n37\n60%| 22%\n29%| 3%\n\n\nTNF inhibitor\netanercept\n20030211\n106\n105\n57%| 11%\n27%| 7%\n\n\nIL-17 inhibitor\nixekizumab\nIXORA-PEDS\n115\n56\n89%| 25%\n78%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab LD\nCADMUS\n37\n37\n78%| 11%\n54%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab HD\nCADMUS\n36\n37\n81%| 11%\n61%| 5%\n\n\nIL-17 inhibitor\nsecukinumab LD\nCAIN457A2310\n40\n41\n80%| 15%\n73%| 2%\n\n\nIL-17 inhibitor\nsecukinumab HD\nCAIN457A2310\n40\n41\n78%| 15%\n68%| 2%\n\n\nTNF inhibitor\netanercept\nCAIN457A2310\n41\n41\n63%| 15%\n29%| 2%\n\n\n\nOpen in a new tab\nHD, high dose; LD, low dose; PASI, Psoriasis Area and Severity Index; & proportion of patients in biologics study arm | proportion of patients in control study arm with response; # compared against methotrexate monotherapy instead of placebo.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q12w, every 12 weeks; RCT, randomized controlled trial; RR, risk ratio. $ dosed at weeks 1, 2, 3, 4, and every 4 weeks thereafter; # compared against methotrexate monotherapy instead of placebo.Funnel plot asymmetry was significant by Egger’s test for PASI90 (p = 0.017) (Supplementary Figure 2B) but not significant for PASI75 (p = 0.243) (Supplementary Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No serious infections were reported except for the study arm with adalimumab 0.4 mg/kg (3%) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; RCT, randomized controlled trial; RD, risk difference; SAE, serious adverse event.Serious adverse events in adults\nSerious adverse event incidences in adults were low in all study arms (up to 3%) with an RR of 1.08 in IL-17 inhibitors brodalumab, ixekizumab and secukinumab, and an RR of 1.09 in the IL-12/23 inhibitor ustekinumab (Supplementary Table 3).Adverse events in children\nSupplementary Figure 1 and Figure 4 show an overview of the frequency of overall AEs, overall infections, URTIs and gastroenteritis in pediatric plaque psoriasis studies with the exception of the secukinumab studies.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The relative incidence of overall AEs and overall infections was higher with etanercept (64 versus 59% and 47 versus 31%, respectively) (Supplementary Figure 1 and Table 4) and ixekizumab (56 versus 45% and 32 versus 25%, respectively) compared to placebo arms.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Supplementary material\nThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.944208/full#supplementary-material\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Materials\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022 this literature search was updated in line with the previously described review protocol to ensure that the most recent publications on pediatric moderate-to-severe psoriasis are included (Figure 1) (13).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Supplementary Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The comparator arm for the adalimumab study was methotrexate while the other four studies were placebo controlled (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RRs ranged from 2.02–7.45 in PASI75 (Figure 2A) and 4.10–29.72 in PASI90 (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI75 treatment responses were seen for ustekinumab 0.375 mg/kg (RR = 7.25, 95% CI 2.83–18.58) and ustekinumab 0.75 mg/kg (RR = 7.45, 95% CI 2.91–19.06) compared to placebo in the CADMUS study (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI90 treatment responses were seen for ixekizumab (RR = 14.50, 95% CI 4.82–43.58) in the IXORA-PEDS study and for secukinumab (RR = 29.72 for low dose and RR = 27.68 for high dose) in the CAIN457A2310 study (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The pooled RR was 4.16 (95% CI 3.21–5.39) for PASI75 (Figure 2A) and 9.28 (95% CI 5.80–14.86) for PASI90 (Figure 2B), indicating that arms with biologics are significantly superior compared to control arms.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drug class\nDrug\nStudy\nNumber of included patients\n\nPASI75&\nPASI90&\n\n\n\n\n\nBiologics study arm\nControl study arm\n\n\n\n\n\n\nTNF inhibitor\nadalimumab LD#\nM04-717\n39\n37\n44%| 22%\n28%| 3%\n\n\nTNF inhibitor\nadalimumab HD#\nM04-717\n38\n37\n60%| 22%\n29%| 3%\n\n\nTNF inhibitor\netanercept\n20030211\n106\n105\n57%| 11%\n27%| 7%\n\n\nIL-17 inhibitor\nixekizumab\nIXORA-PEDS\n115\n56\n89%| 25%\n78%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab LD\nCADMUS\n37\n37\n78%| 11%\n54%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab HD\nCADMUS\n36\n37\n81%| 11%\n61%| 5%\n\n\nIL-17 inhibitor\nsecukinumab LD\nCAIN457A2310\n40\n41\n80%| 15%\n73%| 2%\n\n\nIL-17 inhibitor\nsecukinumab HD\nCAIN457A2310\n40\n41\n78%| 15%\n68%| 2%\n\n\nTNF inhibitor\netanercept\nCAIN457A2310\n41\n41\n63%| 15%\n29%| 2%\n\n\n\nOpen in a new tab\nHD, high dose; LD, low dose; PASI, Psoriasis Area and Severity Index; & proportion of patients in biologics study arm | proportion of patients in control study arm with response; # compared against methotrexate monotherapy instead of placebo.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q12w, every 12 weeks; RCT, randomized controlled trial; RR, risk ratio. $ dosed at weeks 1, 2, 3, 4, and every 4 weeks thereafter; # compared against methotrexate monotherapy instead of placebo.Funnel plot asymmetry was significant by Egger’s test for PASI90 (p = 0.017) (Supplementary Figure 2B) but not significant for PASI75 (p = 0.243) (Supplementary Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No serious infections were reported except for the study arm with adalimumab 0.4 mg/kg (3%) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; RCT, randomized controlled trial; RD, risk difference; SAE, serious adverse event.Serious adverse events in adults\nSerious adverse event incidences in adults were low in all study arms (up to 3%) with an RR of 1.08 in IL-17 inhibitors brodalumab, ixekizumab and secukinumab, and an RR of 1.09 in the IL-12/23 inhibitor ustekinumab (Supplementary Table 3).Adverse events in children\nSupplementary Figure 1 and Figure 4 show an overview of the frequency of overall AEs, overall infections, URTIs and gastroenteritis in pediatric plaque psoriasis studies with the exception of the secukinumab studies.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The relative incidence of overall AEs and overall infections was higher with etanercept (64 versus 59% and 47 versus 31%, respectively) (Supplementary Figure 1 and Table 4) and ixekizumab (56 versus 45% and 32 versus 25%, respectively) compared to placebo arms.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Supplementary material\nThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.944208/full#supplementary-material\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Materials\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022 this literature search was updated in line with the previously described review protocol to ensure that the most recent publications on pediatric moderate-to-severe psoriasis are included (Figure 1) (13).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Supplementary Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022 this literature search was updated in line with the previously described review protocol to ensure that the most recent publications on pediatric moderate-to-severe psoriasis are included (Figure 1) (13).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Supplementary Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022 this literature search was updated in line with the previously described review protocol to ensure that the most recent publications on pediatric moderate-to-severe psoriasis are included (Figure 1) (13).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Supplementary Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The comparator arm for the adalimumab study was methotrexate while the other four studies were placebo controlled (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RRs ranged from 2.02–7.45 in PASI75 (Figure 2A) and 4.10–29.72 in PASI90 (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI75 treatment responses were seen for ustekinumab 0.375 mg/kg (RR = 7.25, 95% CI 2.83–18.58) and ustekinumab 0.75 mg/kg (RR = 7.45, 95% CI 2.91–19.06) compared to placebo in the CADMUS study (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI90 treatment responses were seen for ixekizumab (RR = 14.50, 95% CI 4.82–43.58) in the IXORA-PEDS study and for secukinumab (RR = 29.72 for low dose and RR = 27.68 for high dose) in the CAIN457A2310 study (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The pooled RR was 4.16 (95% CI 3.21–5.39) for PASI75 (Figure 2A) and 9.28 (95% CI 5.80–14.86) for PASI90 (Figure 2B), indicating that arms with biologics are significantly superior compared to control arms.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drug class\nDrug\nStudy\nNumber of included patients\n\nPASI75&\nPASI90&\n\n\n\n\n\nBiologics study arm\nControl study arm\n\n\n\n\n\n\nTNF inhibitor\nadalimumab LD#\nM04-717\n39\n37\n44%| 22%\n28%| 3%\n\n\nTNF inhibitor\nadalimumab HD#\nM04-717\n38\n37\n60%| 22%\n29%| 3%\n\n\nTNF inhibitor\netanercept\n20030211\n106\n105\n57%| 11%\n27%| 7%\n\n\nIL-17 inhibitor\nixekizumab\nIXORA-PEDS\n115\n56\n89%| 25%\n78%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab LD\nCADMUS\n37\n37\n78%| 11%\n54%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab HD\nCADMUS\n36\n37\n81%| 11%\n61%| 5%\n\n\nIL-17 inhibitor\nsecukinumab LD\nCAIN457A2310\n40\n41\n80%| 15%\n73%| 2%\n\n\nIL-17 inhibitor\nsecukinumab HD\nCAIN457A2310\n40\n41\n78%| 15%\n68%| 2%\n\n\nTNF inhibitor\netanercept\nCAIN457A2310\n41\n41\n63%| 15%\n29%| 2%\n\n\n\nOpen in a new tab\nHD, high dose; LD, low dose; PASI, Psoriasis Area and Severity Index; & proportion of patients in biologics study arm | proportion of patients in control study arm with response; # compared against methotrexate monotherapy instead of placebo.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q12w, every 12 weeks; RCT, randomized controlled trial; RR, risk ratio. $ dosed at weeks 1, 2, 3, 4, and every 4 weeks thereafter; # compared against methotrexate monotherapy instead of placebo.Funnel plot asymmetry was significant by Egger’s test for PASI90 (p = 0.017) (Supplementary Figure 2B) but not significant for PASI75 (p = 0.243) (Supplementary Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No serious infections were reported except for the study arm with adalimumab 0.4 mg/kg (3%) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; RCT, randomized controlled trial; RD, risk difference; SAE, serious adverse event.Serious adverse events in adults\nSerious adverse event incidences in adults were low in all study arms (up to 3%) with an RR of 1.08 in IL-17 inhibitors brodalumab, ixekizumab and secukinumab, and an RR of 1.09 in the IL-12/23 inhibitor ustekinumab (Supplementary Table 3).Adverse events in children\nSupplementary Figure 1 and Figure 4 show an overview of the frequency of overall AEs, overall infections, URTIs and gastroenteritis in pediatric plaque psoriasis studies with the exception of the secukinumab studies.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The relative incidence of overall AEs and overall infections was higher with etanercept (64 versus 59% and 47 versus 31%, respectively) (Supplementary Figure 1 and Table 4) and ixekizumab (56 versus 45% and 32 versus 25%, respectively) compared to placebo arms.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The comparator arm for the adalimumab study was methotrexate while the other four studies were placebo controlled (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The comparator arm for the adalimumab study was methotrexate while the other four studies were placebo controlled (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RRs ranged from 2.02–7.45 in PASI75 (Figure 2A) and 4.10–29.72 in PASI90 (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI75 treatment responses were seen for ustekinumab 0.375 mg/kg (RR = 7.25, 95% CI 2.83–18.58) and ustekinumab 0.75 mg/kg (RR = 7.45, 95% CI 2.91–19.06) compared to placebo in the CADMUS study (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI90 treatment responses were seen for ixekizumab (RR = 14.50, 95% CI 4.82–43.58) in the IXORA-PEDS study and for secukinumab (RR = 29.72 for low dose and RR = 27.68 for high dose) in the CAIN457A2310 study (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The pooled RR was 4.16 (95% CI 3.21–5.39) for PASI75 (Figure 2A) and 9.28 (95% CI 5.80–14.86) for PASI90 (Figure 2B), indicating that arms with biologics are significantly superior compared to control arms.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drug class\nDrug\nStudy\nNumber of included patients\n\nPASI75&\nPASI90&\n\n\n\n\n\nBiologics study arm\nControl study arm\n\n\n\n\n\n\nTNF inhibitor\nadalimumab LD#\nM04-717\n39\n37\n44%| 22%\n28%| 3%\n\n\nTNF inhibitor\nadalimumab HD#\nM04-717\n38\n37\n60%| 22%\n29%| 3%\n\n\nTNF inhibitor\netanercept\n20030211\n106\n105\n57%| 11%\n27%| 7%\n\n\nIL-17 inhibitor\nixekizumab\nIXORA-PEDS\n115\n56\n89%| 25%\n78%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab LD\nCADMUS\n37\n37\n78%| 11%\n54%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab HD\nCADMUS\n36\n37\n81%| 11%\n61%| 5%\n\n\nIL-17 inhibitor\nsecukinumab LD\nCAIN457A2310\n40\n41\n80%| 15%\n73%| 2%\n\n\nIL-17 inhibitor\nsecukinumab HD\nCAIN457A2310\n40\n41\n78%| 15%\n68%| 2%\n\n\nTNF inhibitor\netanercept\nCAIN457A2310\n41\n41\n63%| 15%\n29%| 2%\n\n\n\nOpen in a new tab\nHD, high dose; LD, low dose; PASI, Psoriasis Area and Severity Index; & proportion of patients in biologics study arm | proportion of patients in control study arm with response; # compared against methotrexate monotherapy instead of placebo.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q12w, every 12 weeks; RCT, randomized controlled trial; RR, risk ratio. $ dosed at weeks 1, 2, 3, 4, and every 4 weeks thereafter; # compared against methotrexate monotherapy instead of placebo.Funnel plot asymmetry was significant by Egger’s test for PASI90 (p = 0.017) (Supplementary Figure 2B) but not significant for PASI75 (p = 0.243) (Supplementary Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "RRs ranged from 2.02–7.45 in PASI75 (Figure 2A) and 4.10–29.72 in PASI90 (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI75 treatment responses were seen for ustekinumab 0.375 mg/kg (RR = 7.25, 95% CI 2.83–18.58) and ustekinumab 0.75 mg/kg (RR = 7.45, 95% CI 2.91–19.06) compared to placebo in the CADMUS study (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI90 treatment responses were seen for ixekizumab (RR = 14.50, 95% CI 4.82–43.58) in the IXORA-PEDS study and for secukinumab (RR = 29.72 for low dose and RR = 27.68 for high dose) in the CAIN457A2310 study (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The pooled RR was 4.16 (95% CI 3.21–5.39) for PASI75 (Figure 2A) and 9.28 (95% CI 5.80–14.86) for PASI90 (Figure 2B), indicating that arms with biologics are significantly superior compared to control arms.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drug class\nDrug\nStudy\nNumber of included patients\n\nPASI75&\nPASI90&\n\n\n\n\n\nBiologics study arm\nControl study arm\n\n\n\n\n\n\nTNF inhibitor\nadalimumab LD#\nM04-717\n39\n37\n44%| 22%\n28%| 3%\n\n\nTNF inhibitor\nadalimumab HD#\nM04-717\n38\n37\n60%| 22%\n29%| 3%\n\n\nTNF inhibitor\netanercept\n20030211\n106\n105\n57%| 11%\n27%| 7%\n\n\nIL-17 inhibitor\nixekizumab\nIXORA-PEDS\n115\n56\n89%| 25%\n78%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab LD\nCADMUS\n37\n37\n78%| 11%\n54%| 5%\n\n\nIL-12/23 inhibitor\nustekinumab HD\nCADMUS\n36\n37\n81%| 11%\n61%| 5%\n\n\nIL-17 inhibitor\nsecukinumab LD\nCAIN457A2310\n40\n41\n80%| 15%\n73%| 2%\n\n\nIL-17 inhibitor\nsecukinumab HD\nCAIN457A2310\n40\n41\n78%| 15%\n68%| 2%\n\n\nTNF inhibitor\netanercept\nCAIN457A2310\n41\n41\n63%| 15%\n29%| 2%\n\n\n\nOpen in a new tab\nHD, high dose; LD, low dose; PASI, Psoriasis Area and Severity Index; & proportion of patients in biologics study arm | proportion of patients in control study arm with response; # compared against methotrexate monotherapy instead of placebo.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q12w, every 12 weeks; RCT, randomized controlled trial; RR, risk ratio. $ dosed at weeks 1, 2, 3, 4, and every 4 weeks thereafter; # compared against methotrexate monotherapy instead of placebo.Funnel plot asymmetry was significant by Egger’s test for PASI90 (p = 0.017) (Supplementary Figure 2B) but not significant for PASI75 (p = 0.243) (Supplementary Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "RRs ranged from 2.02–7.45 in PASI75 (Figure 2A) and 4.10–29.72 in PASI90 (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI75 treatment responses were seen for ustekinumab 0.375 mg/kg (RR = 7.25, 95% CI 2.83–18.58) and ustekinumab 0.75 mg/kg (RR = 7.45, 95% CI 2.91–19.06) compared to placebo in the CADMUS study (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The highest PASI90 treatment responses were seen for ixekizumab (RR = 14.50, 95% CI 4.82–43.58) in the IXORA-PEDS study and for secukinumab (RR = 29.72 for low dose and RR = 27.68 for high dose) in the CAIN457A2310 study (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The pooled RR was 4.16 (95% CI 3.21–5.39) for PASI75 (Figure 2A) and 9.28 (95% CI 5.80–14.86) for PASI90 (Figure 2B), indicating that arms with biologics are significantly superior compared to control arms.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Funnel plot asymmetry was significant by Egger’s test for PASI90 (p = 0.017) (Supplementary Figure 2B) but not significant for PASI75 (p = 0.243) (Supplementary Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No serious infections were reported except for the study arm with adalimumab 0.4 mg/kg (3%) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "PASI, Psoriasis Area and Severity Index; RCT, randomized controlled trial; RD, risk difference; SAE, serious adverse event.Serious adverse events in adults\nSerious adverse event incidences in adults were low in all study arms (up to 3%) with an RR of 1.08 in IL-17 inhibitors brodalumab, ixekizumab and secukinumab, and an RR of 1.09 in the IL-12/23 inhibitor ustekinumab (Supplementary Table 3).Adverse events in children\nSupplementary Figure 1 and Figure 4 show an overview of the frequency of overall AEs, overall infections, URTIs and gastroenteritis in pediatric plaque psoriasis studies with the exception of the secukinumab studies.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The relative incidence of overall AEs and overall infections was higher with etanercept (64 versus 59% and 47 versus 31%, respectively) (Supplementary Figure 1 and Table 4) and ixekizumab (56 versus 45% and 32 versus 25%, respectively) compared to placebo arms.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "No serious infections were reported except for the study arm with adalimumab 0.4 mg/kg (3%) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "No serious infections were reported except for the study arm with adalimumab 0.4 mg/kg (3%) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Adverse events in children\nSupplementary Figure 1 and Figure 4 show an overview of the frequency of overall AEs, overall infections, URTIs and gastroenteritis in pediatric plaque psoriasis studies with the exception of the secukinumab studies.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The relative incidence of overall AEs and overall infections was higher with etanercept (64 versus 59% and 47 versus 31%, respectively) (Supplementary Figure 1 and Table 4) and ixekizumab (56 versus 45% and 32 versus 25%, respectively) compared to placebo arms.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 1 and Figure 4 show an overview of the frequency of overall AEs, overall infections, URTIs and gastroenteritis in pediatric plaque psoriasis studies with the exception of the secukinumab studies.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The relative incidence of overall AEs and overall infections was higher with etanercept (64 versus 59% and 47 versus 31%, respectively) (Supplementary Figure 1 and Table 4) and ixekizumab (56 versus 45% and 32 versus 25%, respectively) compared to placebo arms.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Supplementary material\nThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.944208/full#supplementary-material\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Materials\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Materials\n\nClick here for additional data file. (55.4KB, pdf) \n\nClick here for additional data file. (18.4KB, DOCX) \n\nClick here for additional data file. (19.6KB, DOCX) \n\nSupplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Click here for additional data file. (473.8KB, docx) \n\nSupplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 1Comparing efficacy (PASI75 RRs) against safety (RD) in the RCTs that reported both outcomes. (A) PASI75 RR versus overall AE RD; (B) PASI75 RR versus overall infection RD.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel Comparing",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 2Funnel plots asymmetry tests, using data from pediatric psoriasis studies (A) PASI75 data (B) PASI90 data, with log-risk ratios displayed on the horizontal axis.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel Funnel",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Supplementary Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  }
]